If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Retevmo™ (selpercatinib) capsules40 mg, 80 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
For information about Retevmo Ongoing Support and financial assistance for eligible patients, including co-pay assistance, please call the Lilly Oncology Support Center at 1-866-472-8663 , Monday through Friday, 8 AM to 10 PM ET.
Date of Last Review: May 14, 2020